"The Report
PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Description
PharmaPoint: Rheumatoid
Arthritis - Japan Drug Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints. It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
The drivers of sales in this
market include the aging population and the increasing prevalence of
RA, as well as the universal healthcare system, which provides ease
of access to physicians and specialists. Barriers to the growth of
this market include the approval process for drugs in Japan, which
requires trials to be conducted in Japanese populations, and the lag
time between the approval and launch of drugs. Biosimilars are
expected to launch in the RA market in Japan during the forecast
period.
View
Full Report at http://www.marketresearchreports.biz/analysis/247062
Scope
- Overview of Rheumatoid
arthritis including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on the
key drugs in the Japan including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in the Japan from 2013-2023.
- Analysis of the impact of
key events as well the drivers and restraints affecting the Japan
Rheumatoid arthritis market.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid arthritis
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in the Japan
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 14
2.3 Upcoming Related Reports 17
3 Disease Overview 18
3.1 Etiology and Pathophysiology 18
3.1.1 Etiology 18
3.1.2 Pathophysiology 18
3.2 Symptoms 23
3.3 Prognosis 24
3.4 Quality of Life 24
4 Disease Management 25
4.1 Diagnosis and Treatment Overview 25
4.1.1 Diagnosis 25
4.1.2 Treatment Guidelines 27
4.1.3 Leading Prescribed Drugs for the Treatment of RA 35
4.1.4 Clinical Practice 36
4.2 Japan 40
5 Competitive Assessment 43
5.1 Overview 43
5.2 Product Profiles - Major Brands 44
5.2.1 Enbrel (etanercept) 44
5.2.2 Humira (adalimumab) 50
5.2.3 Remicade (infliximab) 53
5.2.4 Simponi (golimumab) 58
5.2.5 Cimzia (certolizumab pegol) 63
5.2.6 Orencia (abatacept) 67
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment